TACC3 and glioma: mAb UJ13A was shown to accumulate in gliomas by virtue of disruption of the blood brain barrier locally [71], and another antibody, ERIC-1 armed with radionuclides iodine-131 or yttrium-90, was used in a therapeutic setting in resected glioma cavities with some clinical benefit [72], [73].